CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中的持续性血液学毒性：综述
英文原题：Prolonged haematologic toxicity in CAR-T-cell therapy: A review.
查看英文原题
Prolonged haematologic toxicity in CAR-T-cell therapy: A review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是一种新型免疫疗法，在复发/难治性血液系统恶性肿瘤中取得了令人鼓舞的疗效。随着应用增加，人们对细胞因子释放综合征和神经毒性等免疫介导不良反应的认识不断加深；然而，发生率较高的长期血液学毒性（PHT）仍未受到充分关注。由于不同研究的人群、CAR-T 产品和治疗疾病各异，且PHT定义不一，其发生率、风险因素和管理方式也存在差异。本文叙述CAR-T 治疗后PHT的表现，并总结相关治疗策略的证据，以促进对该毒性的系统认识。
展开英文摘要原文
Chimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized.
Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its rate, risk factors and management vary across studies. In this review, we provide a narrative of PHT occurring in patients following CAR-T-cell therapy; evidence of PHT treatment strategies is also presented, with the aim of contributing to systematic understanding of PHT.
论文信息
- 作者
- Liu Q、Hu T、Li H、Shen Y、Wu D、Ye B
- 单位
- Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Journal of cellular and molecular medicine2023 Dec
- 原文标识
- PubMed 37702530 · DOI 10.1111/jcmm.17930
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →